Patrick G Enright has bought stock on 11 days since Feb 2018

Patrick G. Enright is a seasoned venture capital executive and biopharmaceutical leader, currently serving as a Director at Vera Therapeutics, Inc. (Nasdaq: VERA), where he has been involved since at least 2020 and recently engaged in insider trading activities.( As a co-founder and Managing Director of Longitude Capital since 2006, Enright specializes in healthcare venture investments, with prior roles including Managing Director at Pequot Ventures (2002–2007), where he co-led life sciences investing, and senior executive positions at Valentis Inc., Boehringer Mannheim (Roche), and Sandoz (Novartis).(

Enright holds a B.S. in Biological Sciences from Stanford University and an MBA from the Wharton School of the University of Pennsylvania.( His extensive board experience spans over 20 biotech companies, including current directorships at BioAge Labs (Nasdaq: BIOA), Jazz Pharmaceuticals (Nasdaq: JAZZ), and Zenas BioPharma, as well as past roles at Aimmune Therapeutics (acquired by Nestlé), Corcept Therapeutics, and Vaxcyte.( He owns approximately 5.1 million shares of Vera Therapeutics as a 10% owner, reflecting significant investment commitment.(

Written by Perplexity from public sources.